RxDoctor Payments Data

Paul Settle, MD

Family Medicine · Danville, VANPI 1760408710

Payments from drug & device makers

$716in general payments, 2019–2025

Across 15 payments — averaging $47.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127
  • Novo Nordisk$123
  • AstraZeneca$106
  • Biogen$92
  • Bayer$87
  • Merck$56
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$127
Novo Nordisk2$123
AstraZeneca1$106
Biogen1$92
Bayer1$87
Merck1$56
Gilead2$40
Lilly USA, LLC2$38
Philips North America LLC1$18
Exact Sciences1$15
Atland Pharmaceuticals, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$716 in reported general payments places this provider in the 60th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$221
Medicare patients
12
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide27$41,395
FarxigaDapagliflozin Propanediol27$39,023
MounjaroTirzepatide24$30,615
OzempicSemaglutide22$27,220
EliquisApixaban28$20,340
JardianceEmpagliflozin13$19,806
LinzessLinaclotide33$19,694
Tresiba Flextouch U-200Insulin Degludec12$13,768
Advair HfaFluticasone Propion/Salmeterol16$9,543
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,562
Albuterol Sulfate HfaAlbuterol Sulfate84$2,091
Gabapentin142$1,814
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,501
Atorvastatin Calcium135$1,302
Diclofenac Sodium60$1,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$38$72,01051 claims
AstraZenecaFarxiga$106$39,02327 claims
Novo NordiskOzempic$123$27,22022 claims
AbbVieLinzess$127$19,69433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →